DOCSLIB.ORG

The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes the T-Emerge 2 Trial

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes the T-Emerge 2 Trial Clinical Care/Education/Nutrition/Psychosocial Research ORIGINAL ARTICLE The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes The T-Emerge 2 Trial 1 5 JULIO ROSENSTOCK, MD MARK BOLDRIN, MS low risk of hypoglycemia (1). The most 2 6 BOGDAN BALAS, MD ROBERT RATNER, MD 3 2 common adverse events with exenatide BERNARD CHARBONNEL, MD RAFFAELLA BALENA, MD 4 and liraglutide are gastrointestinal distur- GEREMIA B. BOLLI, MD FOR THE T-EMERGE 2STUDY GROUP* bances such as nausea (8–44 and 8–35%, respectively) and vomiting (4–13 and 7– 12%, respectively), which have limited OBJECTIVEdTaspoglutide is a long-acting glucagon-like peptide 1 receptor agonist devel- fi their use and adherence in clinical prac- oped for treatment of type 2 diabetes. The ef cacy and safety of once-weekly taspoglutide was – compared with twice-daily exenatide. tice (2 5). The investigational GLP-1 receptor ag- RESEARCH DESIGN AND METHODSdOverweight adults with inadequately con- onist taspoglutide has 93% homology with trolled type 2 diabetes on metformin 6 a thiazolidinedione were randomized to subcutaneous endogenous GLP-1 and was considered to taspoglutide 10 mg weekly (n = 399), taspoglutide 20 mg weekly (n = 398), or exenatide 10 mg have potency equivalent to GLP-1 (6). In twice daily (n = 392) in an open-label, multicenter trial. The primary end point was change in short-term phase 2 clinical studies, once- HbA1c after 24 weeks. weekly taspoglutide demonstrated mean- ingful antihyperglycemic and weight loss RESULTSdMean baseline HbA1c was 8.1%. Both doses of taspoglutide reduced HbA1c sig- nificantly more than exenatide (taspoglutide 10 mg: –1.24% [SE 0.09], difference –0.26, 95% CI effects (7,8). Conceivably, weekly adminis- –0.37 to –0.15, P , 0.0001; taspoglutide 20 mg: –1.31% [0.08], difference –0.33, –0.44 to tration of a GLP-1 receptor agonist, such as –0.22, P , 0.0001; exenatide: –0.98% [0.08]). Both taspoglutide doses reduced fasting plasma taspoglutide, could result in beneficial ef- glucose significantly more than exenatide. Taspoglutide reduced body weight (taspoglutide fects on glycemic control as well as greater 10 mg, –1.6 kg; taspoglutide 20 mg, –2.3 kg) as did exenatide (–2.3 kg), which was greater acceptability by patients, enhancing treat- P , than with taspoglutide 10 mg ( 0.05). HbA1c and weight effects were maintained after 52 weeks. ment compliance. More adverse events with taspoglutide 10 and 20 mg than exenatide developed over time (nausea in 53, The American Diabetes Association/ 59, and 35% and vomiting in 33, 37, and 16%, respectively). Allergic and injection-site reactions were more common with taspoglutide. Discontinuations were greater with taspoglutide. Antitaspoglutide European Association for the Study of antibodies were detected in 49% of patients. Diabetes consensus statement, which in- cludes the use of GLP-1 receptor agonists CONCLUSIONSdOnce-weekly taspoglutide demonstrated greater glycemic control than as a secondary option to add to metfor- twice-daily exenatide with comparable weight loss, but with unacceptable levels of nausea/vom- min, recommends head-to-head compar- iting, injection-site reactions, and systemic allergic reactions. ative studies to assess the value of new agents to achieve the currently recom- mended glycemic goals and their safety profiles (9). Accordingly, we designed a lucagon-like peptide 1 (GLP-1) re- liraglutide, a once-daily GLP-1 analog, long-term study (T-Emerge 2) to com- Gceptor agonists have emerged as are currently licensed for the treatment of pare the efficacy and safety of once- antihyperglycemic medications type 2 diabetes. In randomized clinical weekly taspoglutide with twice-daily with added therapeutic value beyond trials, these subcutaneously administered exenatide in patients with type 2 diabetes glucose-lowering properties. Exenatide, compounds have demonstrated antihy- inadequately controlled with metformin, a twice-daily GLP-1 mimetic, and perglycemic and weight loss effects with a thiazolidinedione, or a combination of metformin and thiazolidinedione. Prior ccccccccccccccccccccccccccccccccccccccccccccccccc to the completion of the long-term exten- 1 2 sion arm of this study, the taspoglutide From the Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas; F. Hoffmann-La Roche Ltd., Basel, Switzerland; the 3Department of Internal Medicine, Endocrinology, and Diabetes, University of phase 3 clinical trials were terminated Nantes, Nantes, France; the 4Department of Internal Medicine, University of Perugia, Perugia, Italy; because of a significantly increased rate 5Roche, Nutley, New Jersey; and 6MedStar Health Research Institute, Hyattsville, Maryland. of unwanted adverse events. Neverthe- Corresponding author: Julio Rosenstock, [email protected]. less, we believe that transparent reporting Received 13 April 2012 and accepted 12 August 2012. DOI: 10.2337/dc12-0709. Clinical trial reg. no. NCT00717457, clinicaltrials.gov. of the T-Emerge 2 Study results will pro- This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10 vide important information to help put in .2337/dc12-0709/-/DC1. perspective important safety issues R.B. is currently affiliated with Eli Lilly, Erl Wood Manor, Windlesham Surry, U.K. related to current and future trials with *A complete list of the T-Emerge 2 Study investigators can be found in the Supplementary Data online. © 2012 by the American Diabetes Association. Readers may use this article as long as the work is properly GLP-1 receptor agonists. We report the cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/ key efficacy results from the 24-week, licenses/by-nc-nd/3.0/ for details. open-label, active-controlled core phase care.diabetesjournals.org DIABETES CARE 1 Diabetes Care Publish Ahead of Print, published online November 8, 2012 Taspoglutide compared with exenatide and the 28-week, open-label extension [.240 mg/dL] between weeks 4 and 8, point was determined using ANOVA, phase. We are also presenting the cumu- .12.2 mmol/L [.220 mg/dL] between with treatment, region, and background lative safety data for the entire study up to weeks 8 and 12, and .11.1 mmol/L antihyperglycemic treatment as variables the last dose administered (week 104). [.200 mg/dL] between weeks 12 and and baseline value of the end point as co- 24), additional antihyperglycemic rescue variate. Missing values were imputed as the RESEARCH DESIGN AND medication was prescribed (first choice last observation carried forward. HbA1c METHODSdEligible participants were was a sulfonylurea), and patients contin- was tested in each of the two active arms 18–75 years of age with type 2 diabetes, uedinthestudy. versus exenatide for noninferiority first (if HbA1c between 7 and 10%, and BMI $25 the upper limit of the two-sided 95% CI for kg/m2 (.23 kg/m2 for Asians) and #45 End points and assessments the treatment difference was ,0.4%, a pre- kg/m2 (with stable body weight [65%] for The primary efficacy end point was the specified noninferiority margin). The 3 months), and were receiving a stable dose absolute change from baseline in HbA1c Hochberg procedure was used to control of antihyperglycemic medication (metfor- (%) after 24 weeks of treatment. Second- for the two comparisons. Superiority (if min $1,500 mg/day, a thiazolidinedione ary efficacy end points included changes the upper limit of the two-sided CI limit , [either rosiglitazone $4mg/dayorpioglita- in HbA1c (%), fasting plasma glucose, and was 0) was tested under a gatekeeping zone $30 mg/day], or both) for $3months body weight during 52 weeks of treat- test procedure only if noninferiority was prior to screening. Key exclusion criteria were ment and changes in fasting proinsulin, metinbotharms.Changesinfastingplasma advanced diabetes complications, gastroin- fasting proinsulin-to-insulin ratio, and glucose and body weight were analyzed testinal disease, previous bariatric surgery, homeostasis model assessment of b-cell similarly with the testing sequence. The pancreatitis, cardiovascular disease, or previ- function after 52 weeks of treatment. Ex- other continuous secondary and explor- ous exposure to GLP-1 receptor agonists. ploratory end points included changes in atory end points were assessed using The trial was conducted in accordance lipid profile, high-sensitivity C-reactive ANCOVA but were not part of the testing with the Declaration of Helsinki and national protein, and blood pressure after 52 sequence. HbA1c response rates and related regulations, and the protocol was approved weeks of treatment and the proportion 95% CIs were calculated according to by local independent ethics committees or of patients who received rescue medica- Pearson–Clopper. Patients were included institutional review boards. All participants tion. Samples were assayed by a central in the safety analysis if they received at least provided written consent prior to any pro- laboratory (Covance Central Laboratory, one dose of the study drug and had at least cedure. Geneva, Switzerland). one safety follow-up (or reported an adverse Safety assessments included adverse event). Study design and interventions events, vital signs, physical examinations, T-Emerge 2 was a randomized, open- clinical laboratory tests, electrocardio- RESULTSdThe first participant was label, active-comparator, parallel-group, grams, and testing for antitaspoglutide enrolled on 25 July 2008, and the
Load more

Recommended publications
  • Semaglutide Versus Liraglutide for Treatment of Obesity
    Archives of Diabetes & Obesity DOI: 10.32474/ADO.2021.03.000162 ISSN: 2638-5910 Review Article Semaglutide versus liraglutide for treatment of obesity Nasser Mikhail* *Department of Medicine, Endocrinology Division, David-Geffen UCLA Medical School, USA *Corresponding author: Nasser Mikhail, Endocrinology Division, Department of Medicine, Olive View-UCLA Medical Center, David- Geffen UCLA Medical School, CA, USA Received: April 02, 2021 Published: April 19, 2021 Abstract Background: Once weekly (OW) semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) currently under evaluation for treatment of obesity at a dose of 2.4 mg OW. Objective Methods : To compare weight-loss efficacy and safety of once daily (OD) liraglutide 3.0 mg versus OW semaglutide 2.4 mg. : Pubmed research up to March 31, 2021. Randomized trials, pertinent animal studies, and reviews are included. Search Results terms were glucagon-like peptide-1 receptor agonists, weight loss, obesity, liraglutide, semaglutide, efficacy, safety. semaglutide 2.4 mg. However, marked resemblance between trials in terms of study protocols and subjects’ characteristics may allow indirect: No comparison. head to head In clinical trials are trials available of OW tosemaglutide, provide direct this comparison drug was consistently of efficacy ofassociated OD liraglutide with greater 3.0 mg weightversus lossOW than in trials of OD liraglutide. Thus, placebo-corrected percentage weight reduction was -10.3 to -12.4% and -5.4% with OW semaglutide and OD liraglutide, respectively. In patients with type 2 diabetes, corresponding weight reduction was less pronounced with both drugs being -6.2% and -4.3% with OW semaglutide and OD liraglutide, respectively.
    [Show full text]
  • Exenatide QW: a New Treatment Option for Type 2 Diabetes Offering Ease of Use, Improved Efficacy, and Reduced Side Effects
    FEATURE ARTICLE Commentary: Exenatide QW: A New Treatment Option for Type 2 Diabetes Offering Ease of Use, Improved Efficacy, and Reduced Side Effects Charles F. Shaefer, Jr., MD Editor’s note: Once-weekly exenatide, (also called incretin mimetics) cur- with GLP-1 receptor agonists is the which has recently been approved for rently in use.3,4 only form of anti-diabetes therapy patients with type 2 diabetes, has great Validation of the acceptance offering proven weight loss. Finally, potential as a new diabetes therapy in clinical practice of GLP-1 GLP-1 receptor agonist therapy is in the primary care setting. This receptor agonists can be found in one of the recommended treatment commentary and the feature article that the recently released American strategies offering a low incidence of follows it (p. 95) offer an overview of Diabetes Association (ADA)/ hypoglycemia, an important aspect this new therapeutic tool and important European Association for the Study of diabetes therapy learned from the insights about its clinical utility. In the of Diabetes (EASD) position state- Action to Control Cardiovascular interest of transparency, however, we ment on the management of type 2 Risk in Diabetes trial.6 want to point out that the authors of diabetes, which placed these drugs As clinicians consider what to do both articles are affiliated with Amylin alongside older, well-accepted agents when metformin and lifestyle change Pharmaceuticals, which manufactures such as sulfonylureas (SUs) and do not adequately control a patient’s exenatide QW and markets it under the thiozolidinediones (TZDs) as a sec- A1C, they frequently ask, “incretin 5 trade name Bydureon.
    [Show full text]
  • GLP-1 Receptor Agonists
    Cognitive Vitality Reports® are reports written by neuroscientists at the Alzheimer’s Drug Discovery Foundation (ADDF). These scientific reports include analysis of drugs, drugs-in- development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic interventions, and risk factors. Neuroscientists evaluate the potential benefit (or harm) for brain health, as well as for age-related health concerns that can affect brain health (e.g., cardiovascular diseases, cancers, diabetes/metabolic syndrome). In addition, these reports include evaluation of safety data, from clinical trials if available, and from preclinical models. GLP-1 Receptor Agonists Evidence Summary GLP-1 agonists are beneficial for patients with type 2 diabetes and obesity. Some evidence suggests benefits for Alzheimer’s disease. It is unclear whether it is beneficial for individuals without underlying metabolic disease. Semaglutide seems to be most effective for metabolic dysfunction, though liraglutide has more preclinical data for Alzheimer’s disease. Neuroprotective Benefit: Evidence from many preclinical studies and a pilot biomarker study suggest some neuroprotective benefits with GLP-1 agonists. However, whether they may be beneficial for everyone or only a subset of individuals (e.g. diabetics) is unclear. Aging and related health concerns: GLP-1 agonists are beneficial for treating diabetes and cardiovascular complications relating to diabetes. It is not clear whether they have beneficial effects in otherwise healthy individuals. Safety: GLP-1 agonists are generally safe for most people with minor side effects. However, long-term side effects are not known. 1 Availability: Available Dose: Varies - see Chemical formula: C172H265N43O51 (Liraglutide) as a prescription chart at the end of MW: 3751.262 g/mol medicine.
    [Show full text]
  • The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands
    The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands Clare Louise Wishart Submitted in accordance with the requirements for the degree of Doctor of Philosophy of Science University of Leeds School of Biomedical Sciences Faculty of Biological Sciences September 2013 I Intellectual Property and Publication Statements The candidate confirms that the work submitted is her own and that appropriate credit has been given where reference has been made to the work of others. This copy has been supplied on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement. The right of Clare Louise Wishart to be identified as Author of this work has been asserted by her in accordance with the Copyright, Designs and Patents Act 1988. © 2013 The University of Leeds and Clare Louise Wishart. II Acknowledgments Firstly I would like to offer my sincerest thanks and gratitude to my supervisor, Dr. Dan Donnelly, who has been nothing but encouraging and engaging from day one. I have thoroughly enjoyed every moment of working alongside him and learning from his guidance and wisdom. My thanks go to my academic assessor Professor Paul Milner whom I have known for several years, and during my time at the University of Leeds he has offered me invaluable advice and inspiration. Additionally I would like to thank my academic project advisor Dr. Michael Harrison for his friendship, help and advice. I would like to thank Dr. Rosalind Mann and Dr. Elsayed Nasr for welcoming me into the lab as a new PhD student and sharing their experimental techniques with me, these techniques have helped me no end in my time as a research student.
    [Show full text]
  • Combining a Glucagon-Like Peptide-1 Receptor Agonist with Basal Insulin: the Why and How
    Combining a Glucagon-like Peptide-1 Receptor Agonist with Basal Insulin: The Why and How Case Study Mary is a 61 year-old female diagnosed with type 2 diabetes mellitus (T2DM) 8 years ago. She was initially managed with the combination of lifestyle modification and metformin. Since that time she was treated with a sulfonylurea, but it was discontinued due to symptomatic hypoglycemia. She was also treated with pioglitazone, but significant fluid retention led to it discontinuation. A year-and-a- half ago, basal insulin was added to her lifestyle and metformin management. She now administers 52 units (0.62 units/kg) once daily at bedtime. Since starting basal insulin, she has experienced 3 episodes of mild hypoglycemia. Since her diagnosis, Mary’s HbA1c has never been <7.0%; her current HbA1c is 7.9%. Over the past month, her fasting plasma glucose (FPG) has ranged from 103 mg/dL to 136 mg/dL and her postprandial glucose (PPG) from 164 mg/dL to 213 mg/dL. She has gained 2.6 kg since starting basal insulin and her body mass index is now 31 kg/m2. Her blood pressure is 134/82 mmHg. She experiences occasional tingling in her feet. Eye examination reveals grade 1 retinopathy. Current medications are: metformin 1000mg twice daily, basal insulin 52 units once daily at bedtime, and hydrochlorothiazide 25 mg once daily. Her family physician notes that Mary’s FPG is reasonably well-controlled, yet her HbA1c and PPG remain elevated. He is also concerned about her episodes of hypoglycemia and weight gain and the evidence indicating microvascular damage.
    [Show full text]
  • Predicting Immunogenicity of Peptide Drugs and Their Impurities
    Predicting Immunogenicity of Peptide Drugs and their Impurities using in Silico tools: Taspoglutide Case Study Aimee Mattei MS1, Frances Terry MPH1, Brian J Roberts PhD1, William Martin1, and Anne S De Groot MD1,2 1EpiVax, Inc.; 2Professor (Research) and Director, Institute for Immunology and Informatics, University of Rhode Island, USA Abstract What-if-Machine (WhIM) 15 Example Risk Profile for RLD A : . The peptide drug market is expected to generate $50B in revenue by 2024 but the FDA is Random Mimics the process of synthesizing High H ig h concerned about the number of impurities that may be introduced in the synthetic process. polypeptides and records theoretical Low 10 product impurities created through known . The peptide manufacturing process can result in synthesis-related impurities that can introduce Example Risk Profile for failures in the synthesis process. Random Peptides immunogenic epitopes within the amino acid sequence of the peptide, resulting in an unexpected 5 and undesired immune response against the drug. Each identified impurity is scored for Example Risk Profile for RLD B : putative T cell epitope content (EpiMatrix) Low 0 . EpiMatrix can be used to screen both the drug API sequence and its known peptide-related and cross conservation with the human Impurity Risk Score Risk Impurity impurities for the presence of putative T cell epitope content. proteome (JanusMatrix). -5 . When peptide-related impurities are unknown, the “What if Machine” (WhIM) can perform Impurities are weighted based on assumed probability of occurrence. Graphic for illustrative purposes only theoretical changes to the natural amino acid sequence of the drug substance and measure their -1 0 impact on the putative epitope content of the peptide.
    [Show full text]
  • A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients with Type 2 Diabetes
    1926 Diabetes Care Volume 41, September 2018 Ildiko Lingvay,1 Cyrus V. Desouza,2 A 26-Week Randomized Katarina S. Lalic,3 Ludger Rose,4 Thomas Hansen,5 Jeppe Zacho,5 and Controlled Trial of Semaglutide Thomas R. Pieber6 EMERGING THERAPIES: DRUGS AND REGIMENS Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin Diabetes Care 2018;41:1926–1937 | https://doi.org/10.2337/dc17-2381 OBJECTIVE To investigate the efficacy and safety of once-daily semaglutide in comparison with once-daily liraglutide and placebo in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS This 26-week, multicenter, double-blind trial involved patients diagnosed with 1University of Texas Southwestern Medical Cen- type 2 diabetes with HbA1c 7.0–10.0% (53–86 mmol/mol) and treated with diet ter at Dallas, Dallas, TX and exercise with or without metformin. Patients were randomized 2:2:1 to once- 2University of Nebraska Medical Center, Omaha, daily semaglutide, liraglutide, or placebo in one of four volume-matched doses NE 3Faculty of Medicine, University of Belgrade, and (semaglutide 0.05, 0.1, 0.2, or 0.3 mg and liraglutide 0.3, 0.6, 1.2, or 1.8 mg, with Clinic for Endocrinology, Diabetes and Metabolic both compared within each volume-matched dose group). Primary end point was Diseases, Clinical Center of Serbia, Belgrade, Serbia change in HbA1c from baseline to week 26. 4Institute for Diabetes Research in Munster,¨ RESULTS Munster,¨ Germany 5Novo Nordisk A/S, Søborg, Denmark In total, 705 randomized patients were exposed to trial products.
    [Show full text]
  • Albiglutide Needs Greater Accuracy from Remaining Shots on Goal
    November 18, 2011 Albiglutide needs greater accuracy from remaining shots on goal Evaluate Vantage Victoza is looking increasingly bullet-proof. Novo Nordisk’s once-daily GLP-1 agonist proved superior to GlaxoSmithKline’s once-weekly version, albiglutide, in reducing blood glucose while also showing significant weight loss advantages in type II diabetics. This follows a similar win for Victoza against Amylin Pharmaceuticals’ once-weekly challenger in Bydureon (Amylin scores own goal in Bydureon vs Victoza head-to- head study, March 3, 2011). Albiglutide still has a number of shots on goal – data this week from the Harmony 7 trial was the first from eight phase III studies all nearing completion – with a head-to-head against Merck & Co’s DPP-IV inhibitor Januvia probably the most significant in terms of determining albiglutide’s future role and potential in the diabetes market. Although expectations have never been that high, Glaxo’s product had an opportunity to capitalise on the setbacks to Byetta, Bydureon and Roche’s once-weekly taspoglutide – this first trial read out suggests that opportunity will be limited at best or missed altogether. Playing catch up Glaxo’s decision almost three years ago to embark on an extensive phase III programme for albiglutide, branded Syncria at the time, was seen as a bit of a gamble (Glaxo makes brave decision with phase III trials for Syncria, February 17, 2009). Safety concerns about Amylin’s twice-daily Byetta, the only approved GLP-1 agonist at the time, and the fact albiglutide had a lot of ground to make up on Bydureon and taspoglutide, suggested an uphill struggle for Glaxo’s product which was licensed from Human Genome Sciences in 2004.
    [Show full text]
  • Exenatide: Role in Management of Type 2 Diabetes and Associated Cardiovascular Risk Factors
    Therapy in Practice Exenatide: role in management of Type 2 diabetes and associated cardiovascular risk factors Zin Z Htike1, Kamlesh Khunti2 & Melanie Davies* Practice Points Obesity in Type 2 diabetes poses a challenge in choosing the right combination of glucose-lowering agents, particularly due to the potential side effect of weight gain with many of the existing glucose-lowering medications. One of the incretin-based therapies, the glucagon-like peptide-1 analog, exenatide, is found to be a promising new agent that not only provides glucoregulatory effect in improving glycemic control without increase risk of hypoglycemia but also often results in weight loss. Treatment with exenatide results in reduction in HbA1c comparable to many of the existing glucose-lowering agents including basal insulin analog, galrgine or biphasic insulin aspart. Exenatide is of particular benefit in obese patients with Type 2 diabetes whose control in inadequate on a combination of oral glucose-lowering agents. To date, exenatide is not licensed for use in combination with insulin. SUMMARY Management of Type 2 diabetes, particularly in obese patients, is rather challenging as treatment with the majority of the available glucose-lowering t herapies is often associated with side effects of weight gain and hypoglycemia, in addition to failure to maintain durable glycemic control. The first available glucagon-like peptide-1 analog, exenatide, adds a new t herapeutic option to the currently available glucose-lowering agents for obese patients with Type 2 d iabetes. Both randomized controlled trials and retrospective observational s tudies have shown that treatment with exenatide not only improves glycemic control with a low risk of h ypoglycemia, but also results in concurrent weight loss with the additional benefit of i mprovement in cardiovascular risk factors of hypertension and hyperlipidemia.
    [Show full text]
  • A Network Meta-Analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
    Diabetes Ther DOI 10.1007/s13300-016-0155-1 REVIEW A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus Sheena Kayaniyil . Greta Lozano-Ortega . Heather A. Bennett . Kristina Johnsson . Alka Shaunik . Susan Grandy . Bernt Kartman To view enhanced content go to www.diabetestherapy-open.com Received: December 17, 2015 Ó The Author(s) 2016. This article is published with open access at Springerlink.com ABSTRACT treatment of adults with T2DM inadequately controlled on metformin monotherapy. Introduction: Exenatide is a glucagon-like Methods: A systematic literature review was peptide-1 receptor agonist (GLP-1 RA), conducted to identify randomized controlled approved for treatment of type 2 diabetes trials (RCTs) that investigated GLP-1 RAs mellitus (T2DM). There is limited direct (albiglutide, dulaglutide, exenatide, liraglutide, evidence comparing the efficacy and and lixisenatide) at approved doses in the tolerability of exenatide 2 mg once weekly United States/Europe, added on to metformin (QW) to other GLP-1 RAs. A network only and of 24 ± 6 weeks treatment duration. meta-analysis (NMA) was conducted to A Bayesian NMA was conducted. estimate the relative efficacy and tolerability of Results: Fourteen RCTs were included in the exenatide QW versus other GLP-1 RAs for the NMA. Exenatide QW obtained a statistically significant reduction in glycated hemoglobin (HbA1c) relative to lixisenatide 20 lg once daily. No other comparisons of exenatide QW Electronic supplementary material The online version of this article (doi:10.1007/s13300-016-0155-1) to other GLP-1 RAs were statistically significant contains supplementary material, which is available to for change in HbA1c.
    [Show full text]
  • Subcutaneous Semaglutide, Dulaglutide and Liraglutide 1.2Mg for the Treatment of Type
    North Central London Joint Formulary Committee Factsheet Subcutaneous SEMAGLUTIDE▼ (Ozempic®), DULAGLUTIDE▼ (Trulicity®) and LIRAGLUTIDE 1.2mg (Victoza®) Treatment of Type 2 Diabetes Mellitus Start date: December 2019 Review date: August 2022 Document Control Date Version Action July 2016 1.0 New guideline August 2019 1.1 Subcutaneous semaglutide added as the preferred GLP-1 receptor agonist November 2019 1.2 Supply quantities added Agreed by NCL Shared Care Group: December 2019 FACTSHEET TO FACILITATE PRESCRIBING PLEASE NOTE THIS IS NOT A SHARED CARE GUIDELINE, NOR IS IT A FULL SUMMARY OF DRUG INFORMATION. ALWAYS REFER TO THE MOST RECENT BNF AND/OR SUMMARY OF PRODUCT CHARACTERISTICS. Disclaimer This Fact Sheet is registered at North Central London (NCL) Joint Formulary Committee (JFC) and is intended solely for use by healthcare professionals to aid the treatment of patients within NCL. However, this fact sheet is for guidance only, its interpretation and application remains the responsibility of the individual clinician. If in doubt, contact a senior colleague or expert. Clinicians are advised to refer to the manufacturer’s current prescribing information before treating individual patients. The authors and NCL JFC accept no liability for use of this information from this beyond its intended use. While we have tried to compile accurate information in this document, and to keep it updated in a timely manner, we cannot guarantee that it is fully complete and correct at all times. If you identify information within this document that is inaccurate, please report this to the [email protected]. If a patient is harmed as a consequence of following this document, please complete a local incident report and inform [email protected].
    [Show full text]
  • Victoza® (Liraglutide) Injection LEADER: Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results
    Novo Nordisk Victoza® (liraglutide) NDA 22341 S-027 Endocrinologic and Metabolic Drug Advisory Committee, June 20, 2017 Victoza® (liraglutide) injection LEADER: Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results NDA 22341 S-027 Briefing Document Endocrinologic and Metabolic Drug Advisory Committee June 20, 2017 Advisory Committee Briefing Materials: Available for Public Release Novo Nordisk Victoza® (liraglutide) NDA 22341 S-027 Endocrinologic and Metabolic Drug Advisory Committee, June 20, 2017 2 of 95 1 Executive summary Introduction Liraglutide is an analog with 97% homology to human glucagon-like peptide-1 (GLP-1) and acts as a GLP-1 receptor agonist (GLP-1 RA). Liraglutide (Victoza®) obtained marketing authorization in the United States (US) in 2010 and is currently approved in over 100 countries worldwide. In the US, Victoza® (for subcutaneous injection 1.2 mg and 1.8 mg once-daily) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM) as mono- or combination therapy.1 The exposure to Victoza® in the post-marketing setting is extensive; as of 30 June 2016, the cumulative exposure was estimated to be greater than 6 million patient-years of exposure to Victoza®. The LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) was a cardiovascular outcomes trial designed and conducted to determine the effect and long-term safety of liraglutide versus placebo on cardiovascular outcomes as
    [Show full text]